NCT05954312 2026-03-18
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Phase 1 Recruiting
Clinical Trials
117 trialsNCT05382559 2026-03-02
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT06120075 2026-02-27
ARC-27
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT07435311 2026-02-27
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm
Phase 1 Completed
NCT05381909 2026-02-20
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT05818683 2026-02-13
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06266299 2026-01-28
A Study of KK2269 in Adult Participants With Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Recruiting
NCT07358806 2026-01-22
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.
Phase 1 Recruiting
NCT05006794 2026-01-07
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
Gilead Sciences
Phase 1 Active not recruiting
NCT03595059 2025-12-10
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
Phase 1 Completed
NCT06724042 2025-12-10
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1 Not yet recruiting
NCT06241456 2025-12-09
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT00600496 2025-11-13
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Active not recruiting
NCT04794699 2025-11-12
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
IDEAYA Biosciences
Phase 1 Recruiting
NCT05142189 2025-11-12
LuCa-MERIT-1
BioNTech SE
Phase 1 Recruiting
NCT02817633 2025-10-28
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Tesaro, Inc.
Phase 1 Active not recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT05076760 2025-08-29
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen, Inc.
Phase 1 Recruiting
NCT04666129 2025-08-17
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT04306900 2025-07-29
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT04721015 2025-07-03
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT06769425 2025-06-24
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05919537 2025-04-18
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
Hummingbird Bioscience
Phase 1 Active not recruiting
NCT06925659 2025-04-17
A Study of QLM2011 in Subjects With Advanced Solid Tumors
Qilu Pharmaceutical (Hainan) Co., Ltd.
Phase 1 Not yet recruiting
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT05267470 2025-03-25
FORTITUDE-201
Amgen
Phase 1 Terminated
NCT06868732 2025-03-11
Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1 Not yet recruiting
NCT02300298 2025-02-11
Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
Boehringer Ingelheim
Phase 1 Completed
NCT03854227 2025-01-13
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1 Terminated
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT01705483 2024-11-07
A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies
Astellas Pharma Inc
Phase 1 Terminated
NCT02358473 2024-09-19
Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT04187898 2024-09-19
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Spectrum Pharmaceuticals, Inc
Phase 1 Completed
NCT04747470 2024-09-03
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT05084859 2024-08-09
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Biosplice Therapeutics, Inc.
Phase 1 Terminated
NCT06542731 2024-08-07
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT03435250 2024-07-25
Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
Servier
Phase 1 Terminated
NCT04367090 2023-09-18
Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT00251433 2023-03-31
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Novartis
Phase 1 Terminated
NCT03330106 2023-03-28
A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT05622058 2023-02-27
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT05327231 2022-11-16
IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
InxMed (Shanghai) Co., Ltd.
Phase 1 Completed
NCT05552807 2022-09-23
SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sinocelltech Ltd.
Phase 1 Unknown
NCT01920061 2022-09-13
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Pfizer
Phase 1 Completed
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT03486314 2022-04-18
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT02460367 2022-04-06
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Lumos Pharma
Phase 1 Terminated
NCT04811118 2022-01-31
The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT01362374 2022-01-12
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 1 Completed